Skip to main content

Table 1 Baseline clinical characteristics of patients with systemic sclerosis

From: CD34-selected versus unmanipulated autologous haematopoietic stem cell transplantation in the treatment of severe systemic sclerosis: a post hoc analysis of a phase I/II clinical trial conducted in Japan

  CD34-selected
(n = 11)
Unmanipulated
(n = 8)
p value
Age, years 52.3 ± 7.9 55.8 ± 5.0 0.29
Female, n (%) 8 (73) 7 (88) 0.60
Smokers, n (%) 4 (36) 4 (50) 0.66
Disease duration, median (IQR), years 1.4 (1.2–2.8) 1.2 (0.9–1.7) 0.18
DcSSc with severe skin sclerosis, n (%) 9 (82) 6 (75) 1.00
Modified Rodnan skin score 21.5 ± 9.6 22.9 ± 14.0 0.81
Interstitial pneumonia, n (%) 11 (100) 6 (75) 0.16
Percent predicted FVC 63.1 ± 14.7 83.1 ± 17.3 0.01
Percent predicted DLCO 46.4 ± 17.1 49.8 ± 22.9 0.71
LVEF 70.1 ± 8.0 74.5 ± 6.8 0.29
Anti-Scl70 antibody positive, n (%) 9 (82) 4 (50) 0.32
Previous treatment, n (%) 10 (91) 5 (62.5) 0.26
Corticosteroids, n (%) 10 (91) 5 (62.5) 0.26
Cyclophosphamide, n (%) 4 (36) 3 (38) 1.00
Tacrolimus or cyclosporine, n (%) 3 (27) 2 (35) 1.00
  1. Data are presented as mean ± standard deviation unless otherwise indicated
  2. IQR interquartile range, FVC forced vital capacity, DLCO diffusing capacity of carbon monoxide, LVEF left ventricular ejection fraction